

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2015
(Amt in lakhs)

PART - I

S. No	Particulars	QUARTER ENDED			YEAR ENDED
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
		Un-audited			Audited
1	Income from Operations				
	(a) Net Sales/Income from operations	57.49	31.94	45.17	173.04
	(b) Other Operating Income	0.00	0.00	0.00	0.00
	Total Income from Operations	57.49	31.94	45.17	173.04
2	Expenses				
	a. Consumption of raw materials	5.10	0.00	2.91	0.00
	b. Purchases of stock-in-trade	21.61	10.94	21.25	104.19
	c. Increase/decrease in stock in trade and WIP	5.57	13.56	(2.09)	(0.50)
	d. Power & Fuel	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00
	f. Employees Cost	5.18	3.25	4.44	18.20
	g. Depreciation	2.42	8.67	1.68	13.71
	h. Other expenditure	12.43	11.76	22.82	60.31
	Total	52.31	48.18	51.01	195.91
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)	5.18	(16.24)	(5.84)	(22.87)
4	Other Income	0.00	0.00	7.58	12.42
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	5.18	(16.24)	1.74	(10.45)
6	Finance Cost	0.03	0.15	0.00	0.15
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	5.15	(16.39)	1.74	(10.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities	5.15	(16.39)	1.74	(10.60)
10	Tax expense	0.00	0.00	0.00	0.00
	a) Provision for Taxation	0.00	0.00	0.00	4.05
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00
	c) MAT Credit	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	5.15	(16.39)	1.74	(6.55)
12	Extraordinary items (net of tax expense Rs. Nil)	0.00	0.00	0.00	0.00
13	Net Profit (+)/Loss (-) for the period	5.15	(16.39)	1.74	(6.55)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extra- ordinary items - not annualised)				
	a) Basic	0.15	(0.48)	0.05	(0.19)
	b) Diluted	0.15	(0.48)	0.05	(0.19)
17	Earnings Per Share (after extra- ordinary items - not annualised)				
	a) Basic	0.15	(0.48)	0.05	(0.19)
	b) Diluted	0.15	(0.48)	0.05	(0.19)
PART - II					
A. Particulars of Shareholding					
1	Public shareholding				
	- Number of shares	3,155,397	3,155,886	3166405	3,166,405
	- Percentage of shareholding	92.66%	92.67%	92.98%	92.98%
2	Promoters and Promoter Group				
	Shareholding				
	a) Pledged/Encumbered - No. of Shares	Nil	Nil	NIL	Nil
	percentage of shares	Nil	Nil	NIL	Nil
	(as a % of the total shareholding of promoter and promoter group)				




	(as a % of the total share capital of the Company)				
b	Non - encumbered				
	Number of shares	250,103	249,614	239,095	239,095
	percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	percentage of shares (as a % of the total sharecapital of the company)	7.34%	7.33%	7.02%	7.02%
B.	Particulars	3 months ended 30/06/2015			
	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter				Nil
	Received during the quarter				Nil
	Disposed of during the quarter				Nil
	Remaining unresolved at the end of the quarter				Nil

Notes:

- 1) The above unaudited results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th Aug 2015.
- 2) Figures for the previous Year/Quarter have been rearranged/regrouped wherever necessary.
- 3) The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard-17 on segment reporting issued by the ICAI
- 4) Provisions for Income Tax and Deffered Tax will be made at the end of the Financial Year

PLACE : HYDERABAD
DATE : 14.08.2015

For PHARMAIDS PHARMACEUTICALS LIMITED
Chairman & Managing Director



Date :

LIMITED REVIEW REPORT


We have reviewed the accompanying statement of un-audited financial results of **M/S. PHARMAIDS PHARMACEUTICALS LIMITED, HYDERABAD** for the quarter ended 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' which has been traced from disclosures made by the management and has not been audited by us. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.


Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above, and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognized policies and practices generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rakesh S Jain & Associates
Chartered Accountants
Firm Registration No. 0101298


(ARVIND AGARWAL)
Partner

M. No. 214496



Date: 14.08.2015
Place: Hyderabad.